LEV is inching closer! Rejuvenating mitochondria - Clinical Trials

There are several clinical trials and research initiatives in Japan focused on drugs and therapies aimed at rejuvenating mitochondria. One notable example is the approval of Imeglimin, a first-in-class mitochondria-targeted reagent for type 2 diabetes, by a French biopharmaceutical company, Poxel SA. This drug has been approved for marketing in Japan as of 2021 and has shown favorable safety and tolerability[2]. Imeglimin targets mitochondrial function, which is crucial for its therapeutic effects in diabetes management, indirectly contributing to mitochondrial health. …

biopharmaceutical class clinical clinical trials diabetes drugs example french in japan japan marketing research type